SavedAdd your journal

Journals / Tüberküloz ve Toraks / 2005 / Cilt: 53 - Sayı: 1

The use of FDG-PET scanning in lung cancer

Akciğer kanserlerinde FDG-PET uygulamaları

Kerim SÖNMEZOĞLU
Pages
95–114
Publication Date
2022-11-03
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Further technologic improvements in PET scanners and new more tumor specific radiopharmaceuticals are likely to bring further benefits to the management of patients with lung cancer in the future.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Positron emission tomography (PET) imaging with flurodeoxyglucose (FDG) is a very useful imaging modality that significantly contributes to the diagnosis and staging in patients with lung cancer.
📊
Key Findings & Data:Additionally, FDG-PET has been shown to play an effective role to predict therapy response and to assess tumor aggressiveness as well as to define radiotherapy treatment fields.
💡
Conclusion & Impact:Further technologic improvements in PET scanners and new more tumor specific radiopharmaceuticals are likely to bring further benefits to the management of patients with lung cancer in the future.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Positron emission tomography (PET) imaging with flurodeoxyglucose (FDG) is a very useful imaging modality that significantly contributes to the diagnosis and staging in patients with lung cancer. Additionally, FDG-PET has been shown to play an effective role to predict therapy response and to assess tumor aggressiveness as well as to define radiotherapy treatment fields. Further technologic improvements in PET scanners and new more tumor specific radiopharmaceuticals are likely to bring further benefits to the management of patients with lung cancer in the future.

Özet

Florodeoksiglikoz (FDG) ile pozitron emisyon tomografisi (PET), akciğer kanserli hastaların tanısına ve evrelenmesine önemli oranda katkı yapan bir görüntüleme metodudur. Ayrıca, tümörün tedaviye yanıtını belirlemede, tümör agresifliğini ortaya koymada ve radyoterapi alanını belirlemede FDG-PET’in etkin rol oynadığı ortaya konmuştur. Gelecekte tarayıcı teknolojisindeki ilerlemeler ve tümöre daha spesifik yeni radyofarmasötiklerin geliştirilmesi ile akciğer kanserli hastalara yaklaşımda PET’in daha belirleyici rol oynayacağı öngörülmektedir.

🔖

Cite This Article

SÖNMEZOĞLU, K. (2022). The use of FDG-PET scanning in lung cancer. Tüberküloz ve Toraks, Cilt: 53 - Sayı: 1, 95–114. https://ajindex.com/articles/619192

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Yankelevitz DF, Henschke CI. Does 2 years stability imply that pulmonary nodules are benign? Am J Roentgenol 1997; 168: 325-8
  2. Mack MJ, Hazelrigg SR, Landreneau RJ, Acuff TE. Thoracoscopy for the diagnosis of the indeterminate solitary pulmonary nodule. Ann Thorac Surg 1993; 56: 825-30
  3. Gould MK, Maclean CC, Kuschner WG, et al. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions. JAMA 2001; 285: 914-24
  4. Detterbeck FC, Falen S, Rivera MP, et al. Seeking a home for a PET, part 1: Defining the appropriate place for positron emission tomography imaging in the diagnosis of pulmonary nodules or masses. Chest 2004; 125: 2294-9
  5. Gambhir SS, Hoh CK, Phelps ME, et al. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of NSCLC. J Nucl Med 1996; 37: 1428-36
  6. Webb WR, Gatsonis C, Zerhouni EA, et al. CT and MR imaging in staging non-small cell bronchogenic carcinoma. Radiology 1991; 178: 705-13
  7. Detterbeck FC, Jones DR, Parker LA Jr. Intrathoracic staging. In: Detterbeck FC, Rivera MP, Socinski MA, et al (eds). Diagnosis and Treatment of Lung Cancer: An Evidence Based Guide for the Practicing Clinician. Philadelphia, PA: WB Saunders, 2001: 73-93
  8. Lardinois D, Weder W, Hany TF, et al. Staging of nonsmall cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 2003; 348: 2500-7
  9. Detterbeck F, Falen S, Rivera M, et al. Seeking a home for a PET, part 2: Defining the appropriate place for positron emission tomography imaging in the staging of patients with suspected lung cancer. Chest 2004; 125: 2300-8
  10. Pieterman R, VanPutten J, Meuzelaar J, et al. Preoperative staging of non-small-cell lung cancer with positron emission tomography. N Engl J Med 2000; 343: 254-61
  11. Saunders CAB, Dussek JE, O’Doherty MJ, et al. Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography in the staging of lung cancer. Ann Thorac Surg 1999; 67: 790-7
  12. Gambhir S, Czernin J, Schwimmer J, et al. A tabulated summary of the FDG PET literature. J Nucl Med 2001; 42: 1-92
  13. Dwamena BA, Sonnad SS, Angobaldo JO, et al. Metastases from non-small cell lung cancer: mediastinal staging in the 1990s; meta-analytic comparison of PET and CT. Radiology 1999; 213: 530-6
  14. Toloza EM, Harpole L, McCrory D. Noninvasive staging of non-small cell lung cancer: a review of the current evidence. Chest 2003; 123: 137-46. 1